Day One is a commercial-stage pediatric oncology biopharma with one FDA-approved product (OJEMDA) driving most of the current investment thesis and operational focus.
OJEMDA's April 2024 accelerated approval is a genuine clinical milestone but comes with a confirmatory trial requirement and European approval still pending.
You're here early and that means a lot! ResumeGeni is in Beta which means it isn't 100% finished yet, but every day I'm working towards the vision. It's my goal to help you land your next job.
During the Beta, you'll get access to the state of the art AI to help find your perfect match, and when you do ResumeGeni will prepare your resume to get you to the interview.
There's still a lot to do. Please reach out if you have feedback, a request, or just want to send me a note.
